Cargando…

Single Institutional Experience of Bladder-Preserving Trimodality Treatment for Muscle-Invasive Bladder Cancer

The authors designed this study to determine the clinical effectiveness of trimodality treatment, i.e., transurethral resection of a bladder tumor (TURBT) and concurrent chemoradiotherapy (CRT). Twenty patients with a muscle-invasive bladder cancer were treated by TURBT followed by concurrent cispla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Joung, Jae Young, Han, Kyung Seok, Kim, Taek Sang, Seo, Ho Kyung, Chung, Jinsoo, Lee, Kang Hyun
Formato:	Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2008
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2526414/ https://www.ncbi.nlm.nih.gov/pubmed/18756044 http://dx.doi.org/10.3346/jkms.2008.23.4.598

Ejemplares similares

Trimodality Treatment for Muscle-Invasive Bladder Cancer: An Institutional Experience
por: Polineni, Praneet, et al.
Publicado: (2021)

Trimodality Therapy for Bladder Preservation in the Elderly Population with Invasive Bladder Cancer
por: Turgeon, Guy-Anne, et al.
Publicado: (2014)

Comparison between standard and reduced volume radiotherapy in bladder preservation trimodality protocol for muscle-invasive bladder cancer patients
por: Arafat, Waleed, et al.
Publicado: (2016)

Endoclips as novel fiducial markers in trimodality bladder-preserving therapy of muscle-invasive bladder carcinoma: feasibility and patient outcomes
por: Shahbaz, Muhammad, et al.
Publicado: (2020)

The Role of Transurethral Resection in Trimodal Therapy for Muscle-Invasive Bladder Cancer
por: Russell, Christopher M., et al.
Publicado: (2016)

Editorial Comment: Endoclips as novel fiducial markers in trimodality bladder preserving therapy of muscle-invasive bladder carcinoma: feasibility and patient outcomes
por: dos Reis, Rodolfo Borges, et al.
Publicado: (2020)

Association Between Antibiotic Treatment and the Efficacy of Intravesical BCG Therapy in Patients With High-Risk Non-Muscle Invasive Bladder Cancer
por: Pak, Sahyun, et al.
Publicado: (2021)

The updated outcomes of bladder-preserving trimodal therapy using a real-time tumor-tracking radiotherapy system for patients with muscle-invasive bladder cancer
por: Miyata, Haruka, et al.
Publicado: (2020)

Oncological effectiveness of bladder-preserving trimodal therapy versus radical cystectomy for the treatment of muscle-invasive bladder cancer: a system review and meta-analysis
por: Su, Xiaozhe, et al.
Publicado: (2023)

Recommended oral sodium bicarbonate administration for urine alkalinization did not affect the concentration of mitomycin-C in non-muscle invasive bladder cancer patients
por: Seo, Ho Kyung, et al.
Publicado: (2017)

Outcomes for Muscle-invasive Bladder Cancer with Radical Cystectomy or Trimodal Therapy in US Veterans
por: Kumar, Abhishek, et al.
Publicado: (2021)

A Surgically Treated Case of Ureterovesical Amyloidosis of the Bladder in a Patient with Idiopathic Thrombocytopenia
por: Kim, Sung Han, et al.
Publicado: (2018)

Trimodal Therapy Using an MR–guided Radiation Therapy Partial Bladder Tumor Boost in Muscle Invasive Bladder Cancer
por: Liveringhouse, Casey, et al.
Publicado: (2023)

Detection of Human Papillomavirus Infection and p16 Immunohistochemistry Expression in Bladder Cancer with Squamous Differentiation
por: Kim, Sung Han, et al.
Publicado: (2014)

Bladder Preservation for Muscle Invasive Bladder Cancer
por: Mirza, Arafat, et al.
Publicado: (2016)

Comparison of outcomes between trimodal therapy and radical cystectomy in muscle-invasive bladder cancer: a propensity score matching analysis
por: Kim, Yeon Joo, et al.
Publicado: (2017)

Where are we now and where are we heading in muscle invasive bladder cancer
por: Ku, Ja Hyeon, et al.
Publicado: (2020)

Trimodal Therapy vs. Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Meta-Analysis
por: Ding, Hui, et al.
Publicado: (2020)

Significant clinicopathologic prognostic factors for bladder recurrence, progression, and cancer-specific survival after surgery among patients with upper urinary tract urothelial carcinoma
por: Kim, Sung Han, et al.
Publicado: (2019)

Where are we with bladder preservation for muscle-invasive bladder cancer in 2017?
por: Smelser, Woodson Wade, et al.
Publicado: (2017)

Phase I Clinical Trial of Everolimus Combined with Trimodality Therapy in Patients with Muscle-Invasive Bladder Cancer
por: Bachir, Bassel G., et al.
Publicado: (2017)

Conditional survival of trimodal therapy for nonmetastatic muscle‐invasive bladder cancer: A SEER database analysis
por: Shangguan, Wentai, et al.
Publicado: (2022)

Analysis of MRE11 and Mortality Among Adults With Muscle-Invasive Bladder Cancer Managed With Trimodality Therapy
por: Magliocco, Anthony M., et al.
Publicado: (2022)

Trimodality Therapy in which Concurrent Chemoradiation with Concomitant Boost in Muscle Invasive TCC Urinary Bladder Cancer
por: Mohammed, Ayatallah Ali Youssief, et al.
Publicado: (2023)

Bladder preservation in non-metastatic muscle-invasive bladder cancer (MIBC): a single-institution experience
por: Gerardi, Marianna A., et al.
Publicado: (2016)

Bladder chondrosarcoma plus urothelial carcinoma in recurred transitional cell carcinoma of the upper urinary tract: a case report and literature review
por: Cho, Min Hyun, et al.
Publicado: (2016)

Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy
por: Kool, Ronald, et al.
Publicado: (2021)

Tumor heterogeneity in muscle-invasive bladder cancer
por: Kang, Ho Won, et al.
Publicado: (2020)

Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer
por: Rose, Tracy L., et al.
Publicado: (2016)

Bladder preservation in muscle-invasive bladder cancer: a comprehensive review
por: Hamad, Judy, et al.
Publicado: (2020)

Utilising alternative cystoscopic schedules to minimise cost and patient burden after trimodality therapy for muscle‐invasive bladder cancer
por: Krishnatry, Rahul, et al.
Publicado: (2023)

Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival
por: Lee, Cheng-Yen, et al.
Publicado: (2014)

Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladder
por: Michaelson, M D, et al.
Publicado: (2004)

Editorial comment: bladder preservation as a treatment strategy in muscle-invasive bladder cancer
por: Ajib, Khaled, et al.
Publicado: (2018)

The Effect of Tri-Modality Therapy with Bladder Preservation for Selective Muscle-Invasive Bladder Cancer
por: Zhiyu, Zhang, et al.
Publicado: (2021)

Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer
por: Elsayed, Dalia Hamouda, et al.
Publicado: (2023)

Emerging treatments for bacillus Calmette–Guérin-unresponsive non-muscle-invasive bladder cancer
por: Kim, Hyung Suk, et al.
Publicado: (2021)

Comparing Long-Term Survival Outcomes for Muscle-Invasive Bladder Cancer Patients Who Underwent with Radical Cystectomy and Bladder-Sparing Trimodality Therapy: A Multicentre Cohort Analysis
por: Qiu, Junlan, et al.
Publicado: (2022)

Comparison of trimodality therapy and neoadjuvant chemotherapy combined with radical cystectomy for the survival of muscle-invasive bladder cancer: a population-based analysis
por: Zhou, Yi-Xin, et al.
Publicado: (2023)

Risk of second primary Cancer among bladder Cancer patients: a population-based cohort study in Korea
por: Kwon, Whi-An, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cbe2s73bdtjd9c0m7re3632mr8